检索结果-南通市图书馆

壬基酚对P450arom和MIS基因表达的影响

在线全文

学校读者我要写书评

暂无评论

引用

上海预防医学 2006年第9期18卷 429-431,434页

作者：杨隽仲伟鉴安达龙太北野健安部真一复旦大学公共卫生学院上海200032 上海市疾病预防控制中心上海200336 熊本大学自然科学研究科

[目的]研究壬基酚(p-nonylphenol,NP)对细胞色素P450芳香化酶基因(P450arom)和苗勒氏管抑制物基因(MIS)表达的影响,探索其对鱼类雌激素样作用的分子机制。[方法]日本比目鱼在性分化过程中能随环境因子改变而发育为不同性别,在幼鱼孵化后... 详细信息

[目的]研究壬基酚(p-nonylphenol,NP)对细胞色素P450芳香化酶基因(P450arom)和苗勒氏管抑制物基因(MIS)表达的影响,探索其对鱼类雌激素样作用的分子机制。[方法]日本比目鱼在性分化过程中能随环境因子改变而发育为不同性别,在幼鱼孵化后第30天到第100天性分化敏感期于27℃水温下,给予幼鱼投食NP 100μg/g饲料。分别对各组比目鱼生殖腺做病理组织切片,判断其性别和雌雄比例,并通过原位杂交方法结合RT-PCR分析第100天青年期鱼生殖腺中P450arom和MISmRNA的表达,观察NP对比目鱼性分化标志基因的作用。[结果]NP对27℃水温饲养下的比目鱼幼鱼有一定程度的雌性化诱导作用,成年雌性的百分比为30%,高于27℃水温对照组(0%);比目鱼幼鱼出生后第100天时对其生殖腺进行原位杂交分析显示,P450arom的mRNA在各组的雌鱼卵巢中有明显表达,但在雄鱼精巢中未见表达;而MIS的mRNA在各组的雌鱼卵巢中不表达,却在雄鱼精巢中能见到很明显的表达。RT-PCR分析也显示,P450芳香化酶的mRNA仅仅在雌鱼卵巢中表达,而MIS也仅仅在雄鱼精巢中表达,证实了原位杂交实验的结果。[结论]在日本比目鱼体内,NP染毒可以诱导P450芳香化酶mRNA表达并抑制MIS的mRNA的表达,从而对生殖腺性分化期的幼鱼发挥雌激素样干扰作用。

关键词：壬基酚芳香化酶P450 苗勒氏管抑制物雌激素样作用

玻璃体切割术联合睫状体平坦部晶状体切开摘除术术后晶状体的倾斜和偏心

在线全文

学校读者我要写书评

暂无评论

引用

世界核心医学期刊文摘（眼科学分册） 2006年第9期2卷 56-56页

作者： Ohara K. Kato S. Hori S. kitano S. 杨秀梅(译) 不详 Department of Ophthalmology Graduate School of Medicine 7-3-1 Hongo Bunkyo-ku Tokyo 113- 8655 Japan

Purpose:To investigate intraocular lens(IOL)tilt and decentration following combined vitrectomy and pars plana lensectomy(PPL)with IOL implantation in patients with proliferative diabetic ***:We followed 25 patients with proliferative diabetic retinopathy who underwent PPL and IOL(MA60BM)implantation at the time of pars plana vitrectomy(PPL group),and 25 patients who underwent phacoemulsification and IOL(MA60BM)implantation without vitrectomy(PE group).Intraocular lens tilt and decentration were evaluated quantitatively,using the anterior eye segment analysis system,approximately 12 months after ***:There was no significant difference in IOL tilt(p=0.47)or decentration(p =0.26)between the PPL and PE ***:The present study suggests that tilt and decentration of the IOL are acceptable in combined vitrectomy and pars plana lensectomy.

关键词：玻璃体切割术睫状体平坦部人工晶状体植入术后偏心度摘除术增生性糖尿病视网膜病变糖尿病视网膜病变患者

吉西他滨标准剂量与小剂量疗法在胰腺癌中的比较:一项前瞻性随机研究

在线全文

学校读者我要写书评

暂无评论

引用

世界核心医学期刊文摘（胃肠病学分册） 2006年第8期2卷 51-51页

作者： Sakamoto H. kitano M. Suetomi Y. M. Kudo 郑世成(译) 王顺涛(校) 不详 Department of Gastroenterology and Hepatology Kinki University School of Medicine 377 -20hno-Higashi Osaka-Sayama 589 -8511 Japan

Background: A prospective, randomized study was performed to determine whether gemcitabine infusion at a low dose (250 mg/m2) is comparable or superior to the standard-dose infusion (1000 mg/m2) in terms of the survival period, clinical benefit, and frequency of adverse effects in patients with advanced pancreatic adenocarcinoma. Methods: Twenty-five patients who were histologically proven to have locally advanced pancreatic cancer or pancreatic cancer with distant metastases were initially enrolled in the present study. They were treated with gemcitabine infusion at either a dose of 1000 mg/m2 over 30 min (the standard regimen) on days 1, 8, and 15 of every 4- week cycle or at a dose of 250 mg/m2 over 30 min every week. Survival time, response rate, time to treatment failure, clinical benefit response, and adverse effects were compared between the two groups. Results: Twenty-one patients received gemcitabine for more than 1 month. The median survival period was 7.2 months for patients who received the low-dose infusion regimen, in contrast to 5.2 months for patients administered the standard-dose infusion regimen. The time to treatment failure was 5.6 months for patients in the low-dose infusion regimen, in contrast to 3.4 months for patients in the standard-dose infusion regimen. There were no significant differences in either survival time or time to treatment failure or clinical benefits between the two groups, but the incidence of adverse reactions in patients administered the low-dose therapy was significantly lower than that in patients receiving the standard-dose therapy (P < 0.05). In particular, patients in the standard infusion regimen group experienced more hematologic toxicity than those in the low-dose regimen. Conclusions: These findings suggest that the low-dose gemcitabine infusion regimen can be continuously administered to patients with locally advanced and systemically spreading pancreatic cancer because of its reduced toxicity, resulting in bett

关键词：胰腺癌患者小剂量疗法标准剂量吉西他滨前瞻性随机研究小剂量治疗存活时间不良反应治疗失败临床疗效